Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Zou, Xiaolong ^a   Qiao, Haiquan ^a   Jiang, Xian ^a   Dong, Xuesong ^a   Jiang, Hongchi ^a   Sun, Xueying ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; DEVELOPMENTALLY REGULATED ENDOTHELIAL CELL LOCUS 1; PLASMID VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; CARRIER PROTEIN; EDIL3 PROTEIN, HUMAN; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; BIOSYNTHESIS; COLON TUMOR; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64249159224     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-33     Document Type: Article

References (30)

1. Cancer statistics, 2007. J Ahmedin S Rebecca W Elizabeth M Taylor X Jiaquan JT Michael, CA Cancer J Clin 2007 57 43 66 10.3322/canjclin.57.1.43 17237035
2. The promise of antiangiogenic cancer therapy. MK Oehler R Bicknell, Br J Cancer 2000 82 749 752 10.1054/bjoc.1999.0991 10732738
3. Angiogenesis in cancer, vascular, rheumatoid, and other disease. J Folkman, Nat Med 1995 1 27 31 10.1038/nm0195-27 7584949
4. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the V3 integrin receptor. C Hidai T Zupancic K Penta A Mikhail M Kawana EE Quertermous Y Aoka M Fukagawa Y Matsui D Platika R Auerbach BL Hogan R Snodgrass T Quertermous, Genes Dev 1998 12 21 33 9420328 10.1101/gad.12.1.21
5. Del1 induces integrin signaling and angiogenesis by ligation of v 3. K Penta JA Varner L Liaw C Hidai R Schatzman T Quertermous, J Biol Chem 1998 274 11101 11109 10.1074/jbc.274.16.11101
6. Developmentally-regulated endothelial cell locus-1. T Quertermous H Brigid SH Ralph JZ Thomas, US Patent 5877281 Issued on March 2 1999
7. The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Y Aoka FL Johnson K Penta KK Hirata C Hidai R Schatzman JA Varner T Quertermous, Microvasc Res 2002 2202 64 148 161 10.1006/mvre.2002.2414
8. The role of adhesion molecules, alpha v beta 3, alpha v beta 5 and their ligands in the tumor cell and endothelial cell adhesion. JX Niu WJ Zhang LY Ye LQ Wu GJ Zhu ZH Yang GE Grau JN Lou, Eur J Cancer Prev 2007 16 517 527 10.1097/CEJ.0b013e3280145c00 18090124
9. Expression of developmentally regulated endothelial cell locus-1 was induced by tumor-derived factors including VEGF. M Aoki M Kanamori K Ohmori M Takaishi NH Huh S Nogami T Kimura, Biochem Biophys Res Commun 2005 333 990 995 10.1016/j.bbrc.2005.06.009 15964546
10. Antisense integrin V and 3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. J Li H Tan X Dong Z Xu C Shi X Han H Jiang GW Krissansen X Sun, Digest Liver Dis 2007 39 557 565 10.1016/j.dld.2007.01.025
11. Vasostatin synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. L Ma L Luo H Qiao X Dong S Pan H Jiang GW Krissansen X Sun, J Hepatol 2006 46 98 106 10.1016/j.jhep.2006.07.031 17109987
12. Del1 mediates VSMC adhesion, migration, and proliferation through interaction with integrin v 3. M Rezaee K Penta T Quertermous, Am J Physiol Heart Circ Physiol 2002 282 1924 1932
13. Requirement of vascular integrin avb3 for angiogenesis. PC Brooks RA Clark DA Cheresh, Science 1994 264 569 571 10.1126/science.7512751 7512751
14. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. PC Brooks AMP Montgomery M Rosenfeld RA Reisfeld T Hu G Klier DA Cheresh, Cell 1994 79 1157 1164 10.1016/0092-8674(94)90007-8 7528107
15. An antagonist of integrin avb3 prevents maturation of blood vessels during embryonic neovascularization. CJ Drake DA Cheresh CD Little, J Cell Sci 1995 108 2655 2661 7593306
16. Cell adhesion and angiogenesis. S Stromblad DA Cheresh, Trends Cell Biol 1996 6 460 467 10.1016/0962-8924(96)84942-7 15157502
17. Role of integrins in cell invasion and migration. JD Hood DA Cheresh, Nat Rev Cancer 2002 2 91 100 10.1038/nrc727 12635172
18. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. M Trikha Z Zhou J Timar E Raso M Kennel E Emmell MT Nakada, Cancer Res 2002 62 10 2824 2833 12019160
19. Inhibitors of integrins. GC Tucker, Curr Opin Pharmacol 2002 2 394 402 10.1016/S1471-4892(02)00175-3 12127872
20. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. C Huang M Li C Chen Q Yao, Expert Opin Ther Targets 2008 12 637 645 10.1517/14728222.12.5.637 18410245
21. Consequences of angiogenesis for tumour progression, metastasis and cancer therapy. JW Rak BD St Croix RS Kerbel, Anti-Cancer Drugs 1995 6 3 18 10.1097/00001813-199502000-00001 7538829
22. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. J Dixelius H Larsson T Sasaki K Holmqvist L Lu A Engstrom R Timpl M Welsh L Claesson-Welsh, Blood 2000 95 3403 3411 10828022
23. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. DI Gabrilovich HL Chen KR Girgis HT Cunningham GM Meny S Nadaf D Kavanaugh DP Carbone, Nat Med 1996 2 1096 1103 10.1038/nm1096-1096 8837607
24. Signalling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. I Zachary G Gliki, Cardiovasc Res 2001 49 568 581 10.1016/S0008-6363(00)00268-6 11166270
25. Angiogenesis in cancer and other diseases. P Carmeliet RK Jain, Nature 2000 407 249 257 10.1038/35025220 11001068
26. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. L Zhang JR Conejo-Garcia D Katsaros PA Gimotty M Massobrio G Regnani A Makrigiannakis H Gray, N Engl J Med 2003 348 203 213 10.1056/NEJMoa020177 12529460
27. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. RE Bachelder A Crago J Chung MA Wendt LM Shaw G Robinson AM Mercurio, Cancer Res 2001 61 5736 5740 11479209
28. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. L Zhang N Yang JR Garcia A Mohamed F Benencia SC Rubin D Allman G Coukos, Am J Pathol 2002 161 2295 2309 12466143
29. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. DJ Schoeffner SL Matheny T Akahane V Factor A Berry G Merlino UP Thorgeirsson, Lab Invest 2005 85 608 623 10.1038/labinvest.3700258 15765121
30. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. MP Barr AM Byrne AM Duffy CM Condron M Devocelle P Harriott DJ Bouchier-Hayes JH Harmey, Br J Cancer 2005 92 328 333 15655556